Haematologica, Vol 92, Issue 7, 998-999 doi:10.3324/haematol.10327
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitroviç, Z.
Right arrow Articles by Labar, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitroviç, Z.
Right arrow Articles by Labar, B.

Malignant Lymphomas

FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma

Zdravko Mitroviç, Igor Aurer, Ivo Radman, Radmila Ajdukoviç, Jadranka Sertiç, Boris Labar

From the Division of Hematology, Department of Internal Medicine, University Hospital Center (UHC) and Medical School University of Zagreb, Croatia (ZM, IA, IR, BL); Center for Functional Genomics, UHC and Medical School University of Zagreb, Croatia (JS); Division of Hematology, Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia (RA)

Correspondence: Zdravko Mitroviç, MD, Division of Hematology, Department of Internal Medicine, UHC Zagreb, Rebro, Kispatiçeva 12, 10000 Zagreb, Croatia. Phone: international +385915689754. Fax: international +38512421892. E-mail: mitrovic{at}mef.hr

We investigated the association of Fc{gamma}RIIIa and Fc{gamma}RIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). Fc{gamma}RIIIa and Fc{gamma}RIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via Fc{gamma}RIIIa and Fc{gamma}RIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.

Key words: Fc{gamma}R, single nucleotide polymorphism, rituximab, chemotherapy, diffuse large B-cell lymphoma.




This article has been cited by other articles:


Home page
 JCOHome page
W.-K. Weng, R. S. Negrin, P. Lavori, and S. J. Horning
Immunoglobulin G Fc Receptor Fc{gamma}RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol., January 10, 2010; 28(2): 279 - 284.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein
Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma
Haematologica, August 1, 2008; 93(8): 1265 - 1267.
[Full Text] [PDF]